Agomelatine: Clinical experience and adherence to EMA recommendations for a novel antidepressant

Irish Medical Journal

Volumn 106, Issue 2, 2013, Pages

  Sinnott, C ^a   Morris, M ^a  

^a St Lukes General Hospital Kilkenny   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; ACETAMIDE DERIVATIVE;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; DEPRESSION; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; HEALTH SERVICE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MENTAL HEALTH SERVICE; PATIENT SAFETY; PREMEDICATION; PRESCRIPTION; RETROSPECTIVE STUDY; SEX RATIO; ADOLESCENT; MIDDLE AGED; PRACTICE GUIDELINE;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; GUIDELINE ADHERENCE; HUMANS; LIVER FUNCTION TESTS; MALE; MEDICAL AUDIT; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

MLCS; MLOWN;

EID: 84874090890     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Ayuso-Mateos JL, V̂zquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS, Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G;ODIN Group. Depressive disorders in Europe: prevalence figures from the ODIN study. Br J Psychiatry. 2001 Oct;179:308-16
2. WHO (World Health Organisation). www.who.int/mental_health. Accessed 20th December 2011
3. Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, Goodwin G, Grunze H, Knapp M, Leonard BE, Lieberman J, Nakane Y, Pinder RM, Schatzberg AF, Svestka J, Baumann P, Ghalib K, Markowitz JC, Padberg F, Fink M, Furukawa T, Fountoulakis KN, Jensen P, Kanba S, Riecher-R̂ssler A. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int Neuropsychopharmacol. 2007 Dec;10 Suppl 1:S1-207
4. de Bodinat C, Guardiola-Lemaitre B, Mocâ E, Renard P, Mû-oz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010 Aug;9:628-42.
5. European Medicines Agency [homepage on the internet]. London. [Cited 2011 Dec 11.Human Medicines. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000915/WC500046227.pdf
6. Tjia J, Fischer SH, Raebel MA, Peterson D, Zhao Y, Gagne SJ, Gurwitz JH, Field TS. Baseline and follow-up laboratory monitoring of cardiovascular medications. Ann Pharmacother. 2011 Sep;45:1077-84.
7. Fisher SH, Tjia J, Field TS. Impact of health information technology interventions to improve medication laboratory monitoring for ambulatory patients: a systematic review. J Am Med Inform Assoc. 2010 Dec;17:631-6.
8. Tjia J, Field T, Raebel M, Fischer S, Peterson D, Zhao Y. PS1-40: Laboratory Monitoring of HEDIS Medications in the Ambulatory Setting: The Relative Contribution of Physician and Patient Behavior to Undermonitoring. Clinical Medicine & Research. 2011 Nov 1;9:178-9
9. Guaiana G, Gupta S, Chiodo D, Davies SJC. Agomelatine versus other antidepressive agents for major depression. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD008851. DOI: 10.1002/14651858.CD008851